Renaissance Capital logo

Longboard Pharmaceuticals Priced, Nasdaq: LBPH

Phase 1 biotech formed by Arena Pharmaceuticals developing medicines for neurological diseases.

Industry: Health Care

First Day Return: +4.1%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. We were formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Our small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Our pipeline includes: LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist, that we are advancing in a multiple-ascending dose (MAD) portion of a Phase 1 clinical trial and expect to initiate a Phase 1b/2a clinical trial for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndrome, among others, in the first quarter of 2022; LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist in investigational new drug application (IND)-enabling studies for neurodegenerative diseases associated with neuroinflammation caused by microglial activation, including amyotrophic lateral sclerosis (ALS); and LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator in IND-enabling studies for central nervous system (CNS) neuroinflammatory diseases.
more less

Longboard Pharmaceuticals (LBPH) Performance